Ownership

  • AKAGERA Medicines is a Delaware registered company (2018), and adheres to all of its governance laws and obligations to protect its private shareholders.

  • It is the only majority-owned African biotech company.

  • All 14 million citizens of Rwanda are stakeholders in the company through a private investment on behalf of the Rwanda Social Security Board.

  • There are nine international impact investors as well.

  • The company has an unqualified opinion on its financial audit.

Science

  • AKAGERA Medicines is a clinical company. (Only 10% of biotech startups make it to this stage.)

  • The company has a competitive advantage in creating the delivery system for a long acting injectables.

  • The company has three therapeutics and five vaccine initiatives.

    • The product scope includes strictly humanitarian efforts (i.e., Lassa Fever, TB) and initiatives with high profit potential (i.e., MRSA, NTMs, Avian Flu, HIV, Maternal and Infant RSV)

  • The company has made 79 intellectual property filings on six continents, and has 7 issued patents in the United States in nearly record time.

  • The science team averages over the age of 50, has worked together in some cases for more than two decades, and has already conceived, developed, and commercialized an approved drug in pancreatic cancer.

Funding

  • The company has raised and been awarded more than $60 million in funds from the United States, Europe and Africa.

  • Approximately half of these funds are non-dilutive financing from the European Union, the European Investment Bank, CEPI, and the Bill and Melinda Gates Foundation.

  • The A round of funding was a $1.00 a share, the B round was $7.62 a share, and the C round was $25 a share. (Only 30% of biotech startups make it to a B round of financing.)